21.10.2014 06:01:52
|
Enanta Not To Exercise Co-development Option For ABT-493 - Update
(RTTNews) - Enanta Pharmaceuticals, Inc., (ENTA), a research and development-focused biotechnology company, said it has decided not to exercise its co-development option for ABT-493, the company's next-generation protease inhibitor for hepatitis C virus or HCV being developed in Enanta's collaboration with AbbVie (ABBV).
According to the original collaboration agreement signed in December 2006, Enanta will be eligible for certain regulatory approval milestones as well as royalties on net sales allocable to ABT-493 from worldwide sales of any ABT-493-containing regimens.
Enanta also reached agreement with AbbVie regarding the net sales allocations for royalty calculations for ABT-450-containing regimens, as well as any regimens containing ABT-493.
ABT-450 is the first clinical-stage protease inhibitor candidate developed within the Enanta-AbbVie collaboration, and ABT-493 is the second.
"We believe that the development and commercialization of our HCV protease assets, ABT-450 and ABT-493, are in good hands with the expertise and resources of a global biopharmaceutical company such as AbbVie," said Jay Luly, President and CEO.
Luly said the firm has decided that it is better to use its financial resources generated by these partnered assets to advance the company's other internal proprietary candidates for HCV, including the newly reacquired NS5A program, and to pursue the growth of pipeline beyond HCV with additional candidates in infectious disease and other indications.
ENTA climbed 6.9 percent on Monday to close at $46.59, and slid 1.7 percent in the extended trade.
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu AbbVie Incmehr Nachrichten
16:04 |
S&P 500-Papier AbbVie-Aktie: So viel Gewinn hätte ein Investment in AbbVie von vor einem Jahr eingebracht (finanzen.at) | |
03.02.25 |
Verluste in New York: S&P 500 verbucht zum Handelsende Verluste (finanzen.at) | |
03.02.25 |
Handel in New York: S&P 500 legt den Rückwärtsgang ein (finanzen.at) | |
03.02.25 |
Verluste in New York: S&P 500 präsentiert sich mittags schwächer (finanzen.at) | |
03.02.25 |
S&P 500-Wert AbbVie-Aktie: So viel hätten Anleger mit einem Investment in AbbVie von vor 10 Jahren verdient (finanzen.at) | |
03.02.25 |
Börse New York in Rot: S&P 500 zum Start des Montagshandels schwächer (finanzen.at) | |
31.01.25 |
Börse New York in Rot: S&P 500 notiert letztendlich im Minus (finanzen.at) | |
31.01.25 |
Börse New York in Grün: S&P 500 verbucht am Freitagnachmittag Gewinne (finanzen.at) |
Analysen zu AbbVie Incmehr Analysen
Aktien in diesem Artikel
AbbVie Inc | 184,72 | 0,09% | |
Enanta Pharmaceuticals Inc | 4,58 | -2,14% |